QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

GSK (GSK) Stock Forecast, Price & News

$37.04
-0.23 (-0.62%)
(As of 09/27/2023 ET)
Compare
Today's Range
$36.80
$37.29
50-Day Range
$34.18
$38.07
52-Week Range
$28.77
$39.74
Volume
2.87 million shs
Average Volume
3.37 million shs
Market Capitalization
$75.85 billion
P/E Ratio
4.23
Dividend Yield
3.81%
Price Target
$37.27

GSK MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.6% Upside
$37.27 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.72mentions of GSK in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
1.32%
From $3.79 to $3.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

834th out of 976 stocks

Pharmaceutical Preparations Industry

392nd out of 456 stocks


GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

GSK Price History

GSK Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
GSK Plc Announces Approval Of Arexvy In Japan - Quick Facts
Was selling our GSK shares a big mistake?
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
UPDATE 2-US FDA approves GSK's bone marrow cancer therapy
GSK to open £65m drug factory in Hertfordshire
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Ex-Dividend for 7/13 Dividend
5/18/2023
Dividend Payable
7/13/2023
Last Earnings
7/26/2023
Ex-Dividend for 10/12 Dividend
8/17/2023
Today
9/27/2023
Dividend Payable
10/12/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
69,400
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$37.27
High Stock Price Forecast
$50.43
Low Stock Price Forecast
$24.44
Forecasted Upside/Downside
+0.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$18.50 billion
Pretax Margin
20.26%

Debt

Sales & Book Value

Annual Sales
$36.28 billion
Cash Flow
$4.38 per share
Book Value
$5.79 per share

Miscellaneous

Outstanding Shares
2,047,510,000
Free Float
1,842,757,000
Market Cap
$75.70 billion
Optionable
Optionable
Beta
0.68

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 53)
    CEO & Director
    Comp: $6.02M
  • Ms. Julie Belita Brown (Age 61)
    CFO & Exec. Director
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally JacksonMs. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 57)
    CA, Pres of Corp. Devel.
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    Pres of Global Affairs













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 4 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price forecast for 2023?

8 brokerages have issued 12-month target prices for GSK's shares. Their GSK share price forecasts range from $24.44 to $50.43. On average, they expect the company's stock price to reach $37.27 in the next year. This suggests a possible upside of 0.8% from the stock's current price.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 at the beginning of the year. Since then, GSK stock has increased by 5.2% and is now trading at $36.97.
View the best growth stocks for 2023 here
.

Are investors shorting GSK?

GSK saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 5,570,000 shares, an increase of 14.8% from the August 31st total of 4,850,000 shares. Based on an average trading volume of 3,370,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.3% of the shares of the company are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) issued its quarterly earnings data on Wednesday, July, 26th. The pharmaceutical company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12. The pharmaceutical company had revenue of $8.98 billion for the quarter, compared to the consensus estimate of $8.49 billion. GSK had a net margin of 50.26% and a trailing twelve-month return on equity of 55.93%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, July 26th. Shareholders of record on Friday, August 18th will be given a dividend of $0.3613 per share on Thursday, October 12th. This represents a $1.45 annualized dividend and a yield of 3.91%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.41 per share and currently has a dividend yield of 3.75%. The dividend payout ratio is 16.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK updated its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.99-$2.05 for the period, compared to the consensus EPS estimate of $3.80. The company issued revenue guidance of $39.63 billion-$40.37 billion, compared to the consensus revenue estimate of $37.43 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.68%), JTC Employer Solutions Trustee Ltd (0.67%), Royal Bank of Canada (0.38%), State Street Corp (0.35%), Acadian Asset Management LLC (0.21%) and Camber Capital Management LP (0.20%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $36.97.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $75.70 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.76 on an earnings per share basis.

How many employees does GSK have?

The company employs 69,400 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -